Table 2.
Characteristics of DC vaccines and toxicity after vaccination
| Patient | Number of DCs injected i.v./i.d. (× 106) | TAA expression (%) | Induration at i.d. vaccination site | Constitutional symptoms | ||||
|---|---|---|---|---|---|---|---|---|
| #1 | #2 | #3 | MAGE3 | Survivin | BCMA | |||
| 1 | 20/10 | 19/10 | 20/10 | 73 | 86 | 53 | No | No |
| 1 Revaccination | 16/8 | 12/6 | 18/9 | 36 | 70 | 70 | No | Yes, grade 1–2 |
| 2 | 15/8 | 14/6 | 15/8 | 81 | 78 | 78 | No | No |
| 3 | 13/6 | 11/6 | 14/8 | 67 | 86 | 40 | Yes | Yes, grade 1–2 |
| 3 Revaccination | 9/4 | 5/2 | 8/3 | 75 | 70 | 65 | No | Yes, grade 1–2 |
| 4 | 22/11 | 14/7 | 14/7 | 41a | 29a | 21a | Yes | Yes, grade 1–2 |
| 5 | 16/8 | 15/7 | 10/5 | 68 | 64 | ND | Yes | Yes, grade 1–2 |
| 6 | 16/8 | 8/4 | 8/4 | 45 | 86 | 65 | Yes | Yes, grade 1–2 |
| 7 | 20/10 | 13/6.5 | 14/7 | 49 | 90 | 47 | Yes | Yes, grade 1–2 |
| 8 | 12/6 | 7/3 | 7/3 | 49 | 89 | 68 | No | No |
| 9 | 22/11 | 23/12 | 20/10 | 34 | 81 | 31 | Yes | No |
| 10 | 20/10 | 20/10 | 20/10 | 50 | 65 | 26 | Yes | Yes, grade 1–2 |
| 11 | 16/8 | 21/11 | 17/9 | 60 | 84 | 60 | No | No |
| 12 | 22/11 | 16/8 | 14/7 | 50 | 84 | ND | Yes | Yes, grade 1–2 |
Patients received three DC vaccines with biweekly intervals. i.v. intravenous, i.d. intradermal, TAA tumor-associated antigen
aTAA expression was analyzed after overnight storage at 4 °C due to logistic reasons